Drug Profile
UE 2343
Alternative Names: UE-2343; XanamemLatest Information Update: 19 Apr 2024
Price :
$50
*
At a glance
- Originator University of Edinburgh
- Developer Actinogen Medical
- Class Antidementias; Azabicyclo compounds; Ketones; Pyrazoles; Pyrimidines; Small molecules; Thiophenes
- Mechanism of Action 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Alzheimer's disease; Major depressive disorder
- Preclinical Fragile X syndrome
Most Recent Events
- 15 Apr 2024 UE 2343 receives Innovation Passport under the Innovative Licensing and Access Pathway designation from the UK MHRA for Alzheimer’s disease
- 24 Jan 2024 Efficacy and adverse events data from a phase I PET target occupancy trial in Alzheimer's disease released by Actinogen Medical
- 28 Aug 2023 Chemical structure information added